RPG Life Sciences will host a virtual investors and analysts call on September 3, 2026, at 4:00 pm IST. The session follows the company's strategic announcement and board meeting outcomes released on September 2.

The communication was issued at short notice in line with good governance practices. The company stated that dial-in details and the investors presentation will be shared separately. Meeting details are also available on the corporate website.

Meeting Schedule

The event is scheduled as a group meet for institutional investors and analysts. Rajesh Shirambekar, Head-Legal & Company Secretary, signed the disclosure.

RPG Life Sciences Limited has completed the strategic reorganization of its active pharmaceutical ingredients (API) business by transferring it to a wholly owned subsidiary, RPG Active Pharma (RPGAP). The move aims to sharpen focus on the high-value niche product segment and accelerate growth through specialized management and capital infusion.

The company announced the transaction details in an investor presentation dated September 2, 2026. The restructuring involves the creation of RPGAP as a dedicated vehicle for the API business, separating it from the formulations segment within the parent entity.

Strategic Restructuring and Partnership

RPG Life Sciences has partnered with InvAscent, a pharma-centric private equity firm, to drive value creation in the new subsidiary. Under the agreement, RPGLS retains a 60% stake in RPGAP, while InvAscent holds 40% following a primary issuance valued at approximately ₹243.33 crore.

InvAscent brings over two decades of experience in building businesses across formulations, APIs, healthcare delivery, and medtech. The firm manages assets under management (AUM) exceeding $850 million across four funds. The partnership is expected to facilitate growth capital, industry relationships, and synergies in product selection and M&A.

Expansion Through Acquisitions

To enhance its product portfolio and manufacturing capacity, RPGAP has entered into agreements for two significant acquisitions:

• Actis Generics: RPGAP will acquire 100% of Actis Generics, a fully backward-integrated manufacturer of APIs and complex intermediates based in Visakhapatnam, Andhra Pradesh. The consideration is approximately ₹80 crore, including net working capital. Actis specializes in anti-diabetic and cardiology molecules with established customer relationships.

• Raghava Life Sciences: Via a slump sale mechanism, RPGAP will acquire the factory, product portfolio, and customer relationships of Raghava Life Sciences. The consideration is approximately ₹135 crore, including net working capital. Raghava operates a state-of-the-art facility near Hyderabad with an installed capacity of 300 KL and a portfolio of 29 API molecules, of which 22 are commercialized.

Operational Highlights

The API business, previously operating from a facility in Navi Mumbai, reported external third-party sales of approximately ₹95.1 crore in FY26, in addition to captive sales to RPGLS for its formulations business. The business focuses on high-value, low-volume niche products insulated from price commoditization.

What the Numbers Show

The combined acquisition cost for Actis Generics and Raghava Life Sciences totals approximately ₹215 crore (₹80 crore + ₹135 crore). This figure represents roughly 88% of the ₹243.33 crore equity investment brought in by InvAscent. This alignment suggests that the new partner’s capital is being deployed almost entirely toward immediate capacity expansion and portfolio enhancement rather than general corporate purposes or debt reduction.

Future Outlook

RPGAP positions itself as a zero-debt company with sufficient liquidity for organic and inorganic growth. The subsidiary plans to leverage economies of scale through backward integration and process optimization. The manufacturing capacity is set to increase fourfold through these transactions, supporting a revenue potential of about ₹200 crore at full utilization levels for the Raghava facility alone.